4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity

Por Bartkowiak, Todd, Curran, Michael A.
Publicado no Front Oncol (2015)

Tumor Vaccines Expressing Flt3-Ligand Synergize with CTLA-4 Blockade to Reject Pre-Implanted Tumors

Por Curran, Michael A., Allison, James P.
Publicado em 2009

Editorial: Advances in Combination Tumor Immunotherapy

Por Curran, Michael A., Fox, Bernard A., Redmond, William L.
Publicado no Front Oncol (2015)

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

Por Curran, Michael A., Montalvo, Welby, Yagita, Hideo, Allison, James P.
Publicado em 2010

CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells

Por Quezada, Sergio A., Peggs, Karl S., Curran, Michael A., Allison, James P.
Publicado em 2006

Combination CTLA-4 Blockade and 4-1BB Activation Enhances Tumor Rejection by Increasing T-Cell Infiltration, Proliferation, and Cytokine Production

Por Curran, Michael A., Kim, Myoungjoo, Montalvo, Welby, Al-Shamkhani, Aymen, Allison, James P.
Publicado em 2011

Repertoire Enhancement with Adoptively Transferred Female Lymphocytes Controls the Growth of Pre-Implanted Murine Prostate Cancer

Por Jenq, Robert R., Curran, Michael A., Goldberg, Gabrielle L., Liu, Chen, Allison, James P., van den Brink, Marcel R. M.
Publicado em 2012

Unique potential of 4-1BB agonist antibody to promote durable regression of HPV(+) tumors when combined with an E6/E7 peptide vaccine

Por Bartkowiak, Todd, Singh, Shailbala, Yang, Guojun, Galvan, Gloria, Haria, Dhwani, Ai, Midan, Allison, James P., Sastry, K. Jagannadha, Curran, Michael A.
Publicado no Proc Natl Acad Sci U S A (2015)

Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin

Por Curran, Michael A., Geiger, Theresa L., Montalvo, Welby, Kim, Myoungjoo, Reiner, Steven L., Al-Shamkhani, Aymen, Sun, Joseph C., Allison, James P.
Publicado em 2013

Tumor hypoxia drives immune suppression and immunotherapy resistance

Por Ai, Midan, Budhani, Pratha, Sheng, Jie, Balasubramanyam, Sadhana, Bartkowiak, Todd, Jaiswal, Ashvin R, Ager, Casey R, Haria, Dhwani D, Curran, Michael A
Publicado no J Immunother Cancer (2015)

Gene Therapy-Mediated Reprogramming Tumor Infiltrating T Cells Using IL-2 and Inhibiting NF-κB Signaling Improves the Efficacy of Immunotherapy in a Brain Cancer Model

Por Mineharu, Yohei, Muhammad, AKM Ghulam, Yagiz, Kader, Candolfi, Marianela, Kroeger, Kurt M., Xiong, Weidong, Puntel, Mariana, Liu, Chunyan, Levy, Eva, Lugo, Claudia, Kocharian, Adrina, Allison, James P., Curran, Michael A., Lowenstein, Pedro R., Castro, Maria G.
Publicado em 2012

Peripheral and tumor immune correlates in patients with advanced melanoma treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) monotherapy or in combination with ipilimumab

Por Postow, Michael A, Cardona, Diana M, Taube, Janis M, Anders, Robert A, Taylor, Clive R, Wolchok, Jedd D, Callahan, Margaret K, Curran, Michael A, Lesokhin, Alexander M, Grosso, Joseph F, Horak, Christine E, Cogswell, John, Simon, Jason S, Gupta, Ashok K, Sznol, Mario
Publicado em 2014

Ipilimumab with stereotactic ablative radiation therapy: Phase I results and immunologic correlates from peripheral T-cells

Por Tang, Chad, Welsh, James W., de Groot, Patricia, Massarelli, Erminia, Chang, Joe Y., Hess, Kenneth R., Basu, Sreyashi, Curran, Michael A., Cabanillas, Maria E., Subbiah, Vivek, Fu, Siqing, Tsimberidou, Apostolia M., Karp, Daniel, Gomez, Daniel R., Diab, Adi, Komaki, Ritsuko, Heymach, John, Sharma, Padmanee, Naing, Aung, Hong, David
Publicado no Clin Cancer Res (2016)

Peripheral blood and tumor biomarkers in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab

Por Callahan, Margaret K, Horak, Christine E, Curran, Michael A, Hollman, Travis, Schaer, David A, Yuan, Jianda, Lesokhin, Alexander M, Kitano, Shigehisa, Hong, Quan, Ariyan, Charlotte E, Busam, Klaus J, Feely, William, Jure-Kunkel, Maria, Grosso, Joseph, Simon, Jason S, Korman, Alan J, Wigginton, Jon M, Gupta, Ashok K, Zhang, Xiaoling, Phillips, Therese, Simmons, Pauline, Sznol, Mario, Wolchok, Jedd D
Publicado em 2013

Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype

Por Gabrusiewicz, Konrad, Rodriguez, Benjamin, Wei, Jun, Hashimoto, Yuuri, Healy, Luke M., Maiti, Sourindra N., Thomas, Ginu, Zhou, Shouhao, Wang, Qianghu, Elakkad, Ahmed, Liebelt, Brandon D., Yaghi, Nasser K., Ezhilarasan, Ravesanker, Huang, Neal, Weinberg, Jeffrey S., Prabhu, Sujit S., Rao, Ganesh, Sawaya, Raymond, Langford, Lauren A., Bruner, Janet M., Fuller, Gregory N., Bar-Or, Amit, Li, Wei, Colen, Rivka R., Curran, Michael A., Bhat, Krishna P., Antel, Jack P., Cooper, Laurence J., Sulman, Erik P., Heimberger, Amy B.
Publicado no JCI Insight (2016)